SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 3)

OMEGA THERAPEUTICS, INC.

(Name of Issuer)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

68217N105

(CUSIP Number)

Noubar B. Afeyan, Ph.D.
Flagship Pioneering, 55 Cambridge Parkway, Suite 800E
Cambridge, MA, 02142
(617) 868-1888

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

02/03/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No.

68217N105

Name of reporting person

Flagship V VentureLabs Rx Fund, L.P.

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,088,470.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,088,470.00

Aggregate amount beneficially owned by each reporting person

1,088,470.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

2 %

Type of Reporting Person (See Instructions)

SCHEDULE 13D

CUSIP No.

68217N105

Name of reporting person

Flagship Ventures Fund V, L.P.

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 5,896,386.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 5,896,386.00

Aggregate amount beneficially owned by each reporting person

5,896,386.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

10.6 %

Type of Reporting Person (See Instructions)

SCHEDULE 13D

CUSIP No.

68217N105

Name of reporting person

Flagship Ventures Fund V General Partner LLC

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 6,984,856.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 6,984,856.00

Aggregate amount beneficially owned by each reporting person

6,984,856.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

12.6 %

Type of Reporting Person (See Instructions)

SCHEDULE 13D

CUSIP No.

68217N105

Name of reporting person

Flagship Pioneering Fund VI, L.P.

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 8,617,413.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 8,617,413.00

Aggregate amount beneficially owned by each reporting person

8,617,413.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

15.6 %

Type of Reporting Person (See Instructions)

SCHEDULE 13D

CUSIP No.

68217N105

Name of reporting person

Flagship Pioneering Fund VI General Partner LLC

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 8,617,413.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 8,617,413.00

Aggregate amount beneficially owned by each reporting person

8,617,413.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

15.6 %

Type of Reporting Person (See Instructions)

SCHEDULE 13D

CUSIP No.

68217N105

Name of reporting person

Nutritional Health LTP Fund, L.P.

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 970,588.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 970,588.00

Aggregate amount beneficially owned by each reporting person

970,588.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

1.8 %

Type of Reporting Person (See Instructions)

SCHEDULE 13D

CUSIP No.

68217N105

Name of reporting person

Nutritional Health LTP Fund General Partner LLC

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 970,588.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 970,588.00

Aggregate amount beneficially owned by each reporting person

970,588.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

1.8 %

Type of Reporting Person (See Instructions)

SCHEDULE 13D

CUSIP No.

68217N105

Name of reporting person

Flagship Pioneering Special Opportunities Fund II, L.P.

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 7,508,693.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 7,508,693.00

Aggregate amount beneficially owned by each reporting person

7,508,693.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

13.6 %

Type of Reporting Person (See Instructions)

SCHEDULE 13D

CUSIP No.

68217N105

Name of reporting person

Flagship Pioneering Special Opportunities Fund II General Partner LLC

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 7,508,693.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 7,508,693.00

Aggregate amount beneficially owned by each reporting person

7,508,693.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

13.6 %

Type of Reporting Person (See Instructions)

SCHEDULE 13D

CUSIP No.

68217N105

Name of reporting person

FPN, L.P.

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

ONTARIO, CANADA

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,617,646.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,617,646.00

Aggregate amount beneficially owned by each reporting person

1,617,646.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

2.9 %

Type of Reporting Person (See Instructions)

SCHEDULE 13D

CUSIP No.

68217N105

Name of reporting person

FPN General Partner LLC

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,617,646.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,617,646.00

Aggregate amount beneficially owned by each reporting person

1,617,646.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

2.9 %

Type of Reporting Person (See Instructions)

SCHEDULE 13D

CUSIP No.

68217N105

Name of reporting person

Flagship VentureLabs V, LLC

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 2,197,059.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 2,197,059.00

Aggregate amount beneficially owned by each reporting person

2,197,059.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

4 %

Type of Reporting Person (See Instructions)

SCHEDULE 13D

CUSIP No.

68217N105

Name of reporting person

Flagship VentureLabs V Manager LLC

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 2,197,059.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 2,197,059.00

Aggregate amount beneficially owned by each reporting person

2,197,059.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

4 %

Type of Reporting Person (See Instructions)

SCHEDULE 13D

CUSIP No.

68217N105

Name of reporting person

Flagship Pioneering Fund VII, L.P.

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,329,324.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,329,324.00

Aggregate amount beneficially owned by each reporting person

1,329,324.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

2.4 %

Type of Reporting Person (See Instructions)

SCHEDULE 13D

CUSIP No.

68217N105

Name of reporting person

Flagship Pioneering Fund VII General Partner LLC

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,329,324.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,329,324.00

Aggregate amount beneficially owned by each reporting person

1,329,324.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

2.4 %

Type of Reporting Person (See Instructions)

SCHEDULE 13D

CUSIP No.

68217N105

Name of reporting person

Flagship Pioneering, Inc.

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 22,240,723.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 22,240,723.00

Aggregate amount beneficially owned by each reporting person

22,240,723.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

40.2 %

Type of Reporting Person (See Instructions)

SCHEDULE 13D

CUSIP No.

68217N105

Name of reporting person

Noubar Afeyan

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 29,225,579.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 29,225,579.00

Aggregate amount beneficially owned by each reporting person

29,225,579.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

52.8 %

Type of Reporting Person (See Instructions)

SCHEDULE 13D

Item 1.

Security and Issuer

(a)

Title of Class of Securities:

Common Stock, $0.001 par value per share

(b)

Name of Issuer:

OMEGA THERAPEUTICS, INC.

(c)

Address of Issuer's Principal Executive Offices:

140 First Street, Suite 501, Cambridge, MASSACHUSETTS , 02141.

Item 4.

Purpose of Transaction

Item 4 of the Schedule 13D is hereby amended to include the following: On January 10, 2025, Christian S. Schade, former Growth Partner at Flagship Pioneering, Inc. ("Flagship Pioneering"), resigned as Chairman and a member of the Company's Board of Directors (the "Board"), effective immediately. On January 22, 2025, Ravi Mehrotra, Ph.D., a Partner at Flagship Pioneering, and Robert L. Rosiello, an Executive Partner at Flagship Pioneering, each submitted their resignation as a member of the Board, effective immediately. On February 3, 2025, the Company entered into a Restructuring Support Agreement (together with all exhibits and schedules thereto, the "RSA") with Pioneering Medicines 08-B, Inc. (the "Supporting Party"), an affiliate of Flagship Pioneering, and certain funds affiliated with Flagship Pioneering that, collectively, are, significant stockholders of the Company. The RSA and related transactions contemplate a potential sale of all or substantially all of the Company's assets and the entry into debtor-in-possession financing to fund the sale process and wind down. Specifically, the RSA provides, in pertinent part, that the following financing transactions will occur, the proceeds of which will be used to fund the operational needs of the Company as the debtor-in-possession in a voluntary proceeding under Chapter 11 of the United States Code, 11 U.S.C. $$ 101-1532, as amended from time to time (any such case, the "Chapter 11 Case") in the United States Bankruptcy Court for the District of Delaware (the "Bankruptcy Court") and to fund the administration of the Debtor's Chapter 11 Case, among other fees and expenses: Pursuant to the RSA, the Supporting Party, as bridge lender, has agreed to make a bridge term loan (the "Bridge Loan") to the Company in a total aggregate principal amount of approximately $1,400,000, in the form of a secured promissory note. The Bridge Loan will be secured by a first priority, senior security interest in substantially all of the assets now owned or hereafter acquired by the Company or in which the Company otherwise has rights and all proceeds thereof, subject only to certain permitted liens, and will be funded upon signing of the RSA. Pursuant to the RSA, the Supporting Party, as post-petition lender to the debtor-in-possession, has agreed to make a senior secured superpriority debtor-in-possession loan (the "DIP Loan") to the Company consisting of (a) new money term loan commitments from the Supporting Party and (b) a roll-up of the Bridge Loan (the "Roll-Up Loans"). The DIP Facility will be secured by certain superpriority and continuing security interests in substantially all of the assets now owned or hereafter acquired by the Company or in which the Company otherwise has rights and all proceeds thereof, subject only to certain permitted liens. The DIP Loan will include certain covenants, including delivery by the Company of a statement of cash receipts and disbursements on a weekly basis. Pursuant to the RSA, the Company will negotiate in good faith a stalking horse asset purchase agreement with the Supporting Party (or a designee thereof), as purchaser, for the sale of substantially all of the Company's assets, and which will contain customary, market bid protections. The transactions contemplated by the RSA (other than the Bridge Loan), including the use of proceeds from the DIP Loan, are subject to and conditioned upon, among other things, approval by the Bankruptcy Court. Pursuant to the RSA, the Company and the Supporting Party have made certain customary covenants to each other. The RSA also includes certain milestones (the "Milestones") for the progress of the Chapter 11 Case, which include, unless otherwise agreed (i) commencement of the Chapter 11 Case by no later than February 10, 2025, at 11:59 a.m. (ET), (ii) approval, no later than 30 days after the Petition Date, of the DIP Loan by the Bankruptcy Court, (iii) conclusion of an auction for the Company's assets no later than 55 days after the Petition Date, and (iv) entry of an order approving the sale by the Bankruptcy Court no later than 60 days after the Petition Date, with the sale being consummated no later than 70 days following the Petition Date. The RSA may be terminated upon, among other things: (i) the failure to meet the Milestones; (ii) the occurrence of certain breaches of the RSA; (iii) the mutual agreement of the parties; and (iv) in the case of the Company, if the Board of the Company reasonably determines in good faith and based upon advice of outside legal counsel that performance under the RSA would be inconsistent with its applicable fiduciary duties. Although the Company intends to pursue the transactions in accordance with the terms set forth in the RSA, there can be no assurance that the Company will be successful in completing the transactions contemplated thereby, whether on the same or different terms or at all.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Flagship V VentureLabs Rx Fund, L.P.

Signature:	/s/ Noubar B. Afeyan, Ph.D.
Name/Title:	Noubar B. Afeyan, Ph.D., Manager of General Partner
Date:	02/05/2025

Flagship Ventures Fund V, L.P.

Signature:	/s/ Noubar B. Afeyan, Ph.D.
Name/Title:	Noubar B. Afeyan, Ph.D., Manager of General Partner
Date:	02/05/2025

Flagship Ventures Fund V General Partner LLC

Signature:	/s/ Noubar B. Afeyan, Ph.D.
Name/Title:	Noubar B. Afeyan, Ph.D., Chief Executive Officer of Manager of General Partner
Date:	02/05/2025

Flagship Pioneering Fund VI, L.P.

Signature:	/s/ Noubar B. Afeyan, Ph.D.
Name/Title:	Noubar B. Afeyan, Ph.D., Chief Executive Officer of Manager of General Partner
Date:	02/05/2025

Flagship Pioneering Fund VI General Partner LLC

Signature:	/s/ Noubar B. Afeyan, Ph.D.
Name/Title:	Noubar B. Afeyan, Ph.D., Chief Executive Officer of Manager of General Partner
Date:	02/05/2025

Nutritional Health LTP Fund, L.P.

Signature:	/s/ Noubar B. Afeyan, Ph.D.
Name/Title:	Noubar B. Afeyan, Ph.D., Chief Executive Officer of Manager of General Partner
Date:	02/05/2025

Nutritional Health LTP Fund General Partner LLC

Signature:	/s/ Noubar B. Afeyan, Ph.D.
Name/Title:	Noubar B. Afeyan, Ph.D., Chief Executive Officer of Manager of General Partner
Date:	02/05/2025

Flagship Pioneering Special Opportunities Fund II, L.P.

Signature:	/s/ Noubar B. Afeyan, Ph.D.
Name/Title:	Noubar B. Afeyan, Ph.D., Chief Executive Officer of Manager of General Partner
Date:	02/05/2025

Flagship Pioneering Special Opportunities Fund II General Partner LLC

Signature:	/s/ Noubar B. Afeyan, Ph.D.
Name/Title:	Noubar B. Afeyan, Ph.D., Manager
Date:	02/05/2025

FPN, L.P.

Signature:	/s/ Noubar B. Afeyan, Ph.D.
Name/Title:	Noubar B. Afeyan, Ph.D., Chief Executive Officer of Manager
Date:	02/05/2025

FPN General Partner LLC

Signature:	/s/ Noubar B. Afeyan, Ph.D.
Name/Title:	Noubar B. Afeyan, Ph.D., Chief Executive Officer of Manager
Date:	02/05/2025

Flagship VentureLabs V, LLC

Signature:	/s/ Noubar B. Afeyan, Ph.D.
Name/Title:	Noubar B. Afeyan, Ph.D., Chief Executive Officer of Manager
Date:	02/05/2025

Flagship VentureLabs V Manager LLC

Signature:	/s/ Noubar B. Afeyan, Ph.D.
Name/Title:	Noubar B. Afeyan, Ph.D., Chief Executive Officer of Manager
Date:	02/05/2025

Flagship Pioneering Fund VII, L.P.

Signature:	/s/ Noubar B. Afeyan, Ph.D.
Name/Title:	Noubar B. Afeyan, Ph.D., Chief Executive Officer of Manager
Date:	02/05/2025

Flagship Pioneering Fund VII General Partner LLC

Signature:	/s/ Noubar B. Afeyan, Ph.D.
Name/Title:	Noubar B. Afeyan, Ph.D., Chief Executive Officer of Manager
Date:	02/05/2025

Flagship Pioneering, Inc.

Signature:	/s/ Noubar B. Afeyan, Ph.D.
Name/Title:	Noubar B. Afeyan, Ph.D., Chief Executive Officer
Date:	02/05/2025

Noubar Afeyan

Signature:	/s/ Noubar B. Afeyan, Ph.D.
Name/Title:	Noubar B. Afeyan, Ph.D.
Date:	02/05/2025

Amendment: SEC Form SCHEDULE 13D/A filed by Omega Therapeutics Inc.